Share on LinkedInShare on LinkedIn

ARTICLE · 10 JULY 2020

Proposed Revisions To Form 3542 With Explanations

Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Contributor
Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP is one of the world’s largest firms focusing on...

View firm profile
Explore more from Finnegan, Henderson, Farabow, Garrett & Dunner LLP

In 1978, the FDA Commissioner announced the FDA's intent to provide a list of all prescription drug products approved by the FDA for safety and effectiveness under the Federal Food, Drug...

United StatesIntellectual Property

In 1978, the FDA Commissioner announced the FDA's intent to provide a list of all prescription drug products approved by the FDA for safety and effectiveness under the Federal Food, Drug, and Cosmetic Act (FD&C Act). This list evolved into the current Orange Book. It included and continues to include only prescription drug products approved by the FDA and marketed at the time of publication. The main criterion for the inclusion of a product is that it has a new drug application (NDA) or abbreviated new drug application (ANDA) that has been approved by the FDA and that has not been withdrawn for safety or efficacy reasons. A first version of the list was published on Oct. 31, 1980. The current version can be found on the FDA's website at Approved Drug Products with Therapeutic Equivalence Determinations, http://www.fda.gov/cder/ob/default.htm.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from